+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Opioids - Global Strategic Business Report

  • PDF Icon

    Report

  • 189 Pages
  • November 2024
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 5309783
The global market for Opioids was estimated at US$27.0 Billion in 2023 and is projected to reach US$31.7 Billion by 2030, growing at a CAGR of 2.3% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

How Has the Opioid Market Evolved Amid Growing Concerns Over Addiction and Regulation?

The global opioids market has been at the center of significant scrutiny and change in recent years due to rising concerns over opioid addiction, abuse, and the corresponding public health crisis. Opioids, a class of drugs that includes prescription painkillers like oxycodone, morphine, and hydrocodone, as well as illicit drugs like heroin, have been widely used for pain management. However, the over-prescription and misuse of these drugs have led to widespread addiction and a global opioid epidemic, particularly in North America. As a result, regulatory authorities worldwide have introduced stricter guidelines on opioid prescriptions, leading to a decline in the use of these drugs for chronic pain. The pharmaceutical industry has also responded by developing abuse-deterrent formulations (ADFs) designed to reduce the potential for misuse. Additionally, the focus is shifting towards non-opioid alternatives for pain management, driving research into new therapies and pain relief methods that minimize the risk of addiction.

What Trends Are Influencing the Opioid Market Today?

Several key trends are shaping the opioid market, reflecting the growing emphasis on reducing opioid-related harm and the development of safer alternatives for pain management. One of the most significant trends is the increasing regulation of opioid prescriptions, particularly in the United States, where the opioid crisis has been most severe. Healthcare providers are now being encouraged to explore non-opioid treatments and to use opioids only as a last resort for managing pain. This trend has led to a decline in opioid prescriptions in many developed markets. Another important trend is the development of abuse-deterrent formulations (ADFs), which are designed to make it more difficult to misuse prescription opioids. These ADFs are gaining traction as pharmaceutical companies and regulators seek to address the issue of opioid abuse while still providing effective pain relief for patients with legitimate medical needs. Additionally, there is growing interest in alternative pain management therapies, including non-opioid drugs, physical therapy, and behavioral interventions, as the medical community looks for ways to manage pain without the risks associated with opioids.

How Is Technology and Research Shaping the Future of Opioids?

Technology and research are playing a key role in shaping the future of the opioid market, with significant efforts being made to develop safer pain management options and reduce the potential for misuse. Pharmaceutical companies are focusing on the development of abuse-deterrent formulations (ADFs) that are resistant to tampering, making it more difficult for individuals to crush, snort, or inject the drugs. These ADFs are designed to maintain the therapeutic benefits of opioids while minimizing the potential for abuse. Advances in drug delivery systems, such as extended-release formulations, are also helping to provide consistent pain relief with lower doses, reducing the risk of dependence. Research into non-opioid painkillers, such as cannabinoids, gabapentinoids, and nerve blockers, is gaining momentum, offering promising alternatives to traditional opioids. Additionally, digital health technologies, including pain management apps and telemedicine, are providing new ways for patients to manage chronic pain without relying on opioids, offering a more holistic approach to pain management.

What Is Driving the Growth in the Opioid Market?

The growth in the opioid market is driven by several factors, including the ongoing need for effective pain management, particularly in cases of acute and postoperative pain. While there is a growing emphasis on reducing opioid use due to addiction concerns, opioids remain an important option for managing severe pain, such as that experienced by cancer patients or individuals recovering from major surgery. The development of abuse-deterrent formulations (ADFs) is driving growth in the prescription opioid market, as these formulations offer a safer alternative to traditional opioids. However, regulatory pressures and increased scrutiny are causing a shift towards non-opioid pain management options, limiting the growth potential in some regions. The aging population, particularly in developed markets, is also contributing to the demand for pain management solutions, as older adults are more likely to experience chronic pain conditions. Additionally, the expansion of healthcare access in emerging markets is supporting growth in opioid demand for pain management, though regulatory frameworks in these regions are becoming more stringent to prevent abuse.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Extended-Release / Long-Acting Opioids segment, which is expected to reach US$18.7 Billion by 2030 with a CAGR of a 2.9%. The Immediate-Release / Short-Acting Opioids segment is also set to grow at 1.5% CAGR over the analysis period.
  • Regional Analysis: Gain insights into the U.S. market, which was valued at $7.3 Billion in 2023, and China, forecasted to grow at an impressive 3.7% CAGR to reach $6.0 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Opioids Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Opioids Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Opioids Market expected to evolve by 2030?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2030?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of major players such as Egalet Corporation, Janssen Pharmaceuticals, Inc., Pfizer, Inc., and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Select Competitors (Total 31 Featured):

  • Egalet Corporation
  • Janssen Pharmaceuticals, Inc.
  • Pfizer, Inc.
  • Purdue Pharma LP
  • Sanofi
  • Sun Pharmaceutical Industries Ltd.
  • West-Ward Pharmaceuticals Corporation

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Global Economic Update
  • Opioids - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • Rising Prevalence of Chronic Pain Conditions Propels Demand for Opioid-Based Pain Management
  • Increased Use of Opioids in Postoperative and Cancer Pain Treatment Strengthens Market Growth
  • Regulatory Pressure to Curb Opioid Abuse Creates Challenges and Drives Innovation in Abuse-Deterrent Formulations
  • Rising Awareness of Opioid Addiction Risks Spurs Development of Non-Addictive Alternatives for Pain Relief
  • Increasing Focus on Patient Monitoring and Prescription Regulations Expands Demand for Secure Opioid Distribution Channels
  • Growth of Palliative Care and End-of-Life Pain Management Fuels Demand for Opioid Medications
  • Surging Demand for Abuse-Deterrent Formulations Strengthens the Business Case for Safer Opioid Products
  • Rising Incidence of Post-Surgical Pain Conditions Sustains Demand for Opioids in Acute Pain Management
  • Expansion of Opioid Use in Treating Severe Trauma Injuries Generates Continued Demand in Emergency Settings
  • Increasing Focus on Pain Management in Aging Populations Drives Opioid Market Growth in Elderly Care
  • Growing Shift Toward Multimodal Pain Management Techniques Challenges Long-Term Use of Opioids
  • Introduction of Non-Opioid Pain Relievers and Alternatives Poses Competitive Pressure on the Opioid Market
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Opioids Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • Table 2: World Recent Past, Current & Future Analysis for Opioids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 3: World Historic Review for Opioids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 4: World 16-Year Perspective for Opioids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
  • Table 5: World Recent Past, Current & Future Analysis for Extended-Release / Long-Acting by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 6: World Historic Review for Extended-Release / Long-Acting by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 7: World 16-Year Perspective for Extended-Release / Long-Acting by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 8: World Recent Past, Current & Future Analysis for Immediate-Release / Short-Acting by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 9: World Historic Review for Immediate-Release / Short-Acting by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 10: World 16-Year Perspective for Immediate-Release / Short-Acting by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 11: World Recent Past, Current & Future Analysis for Pain Relief by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 12: World Historic Review for Pain Relief by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 13: World 16-Year Perspective for Pain Relief by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 14: World Recent Past, Current & Future Analysis for Anesthesia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 15: World Historic Review for Anesthesia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 16: World 16-Year Perspective for Anesthesia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 17: World Recent Past, Current & Future Analysis for Cough Suppression by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 18: World Historic Review for Cough Suppression by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 19: World 16-Year Perspective for Cough Suppression by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 20: World Recent Past, Current & Future Analysis for Diarrhea Suppression by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 21: World Historic Review for Diarrhea Suppression by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 22: World 16-Year Perspective for Diarrhea Suppression by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 23: World Recent Past, Current & Future Analysis for Deaddiction by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 24: World Historic Review for Deaddiction by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 25: World 16-Year Perspective for Deaddiction by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
III. MARKET ANALYSIS
UNITED STATES
  • Opioids Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • Table 26: USA Recent Past, Current & Future Analysis for Opioids by Segment - Extended-Release / Long-Acting and Immediate-Release / Short-Acting - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 27: USA Historic Review for Opioids by Segment - Extended-Release / Long-Acting and Immediate-Release / Short-Acting Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 28: USA 16-Year Perspective for Opioids by Segment - Percentage Breakdown of Value Sales for Extended-Release / Long-Acting and Immediate-Release / Short-Acting for the Years 2014, 2024 & 2030
  • Table 29: USA Recent Past, Current & Future Analysis for Opioids by End-Use - Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 30: USA Historic Review for Opioids by End-Use - Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 31: USA 16-Year Perspective for Opioids by End-Use - Percentage Breakdown of Value Sales for Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction for the Years 2014, 2024 & 2030
CANADA
  • Table 32: Canada Recent Past, Current & Future Analysis for Opioids by Segment - Extended-Release / Long-Acting and Immediate-Release / Short-Acting - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 33: Canada Historic Review for Opioids by Segment - Extended-Release / Long-Acting and Immediate-Release / Short-Acting Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 34: Canada 16-Year Perspective for Opioids by Segment - Percentage Breakdown of Value Sales for Extended-Release / Long-Acting and Immediate-Release / Short-Acting for the Years 2014, 2024 & 2030
  • Table 35: Canada Recent Past, Current & Future Analysis for Opioids by End-Use - Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 36: Canada Historic Review for Opioids by End-Use - Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 37: Canada 16-Year Perspective for Opioids by End-Use - Percentage Breakdown of Value Sales for Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction for the Years 2014, 2024 & 2030
JAPAN
  • Opioids Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • Table 38: Japan Recent Past, Current & Future Analysis for Opioids by Segment - Extended-Release / Long-Acting and Immediate-Release / Short-Acting - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 39: Japan Historic Review for Opioids by Segment - Extended-Release / Long-Acting and Immediate-Release / Short-Acting Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 40: Japan 16-Year Perspective for Opioids by Segment - Percentage Breakdown of Value Sales for Extended-Release / Long-Acting and Immediate-Release / Short-Acting for the Years 2014, 2024 & 2030
  • Table 41: Japan Recent Past, Current & Future Analysis for Opioids by End-Use - Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 42: Japan Historic Review for Opioids by End-Use - Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 43: Japan 16-Year Perspective for Opioids by End-Use - Percentage Breakdown of Value Sales for Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction for the Years 2014, 2024 & 2030
CHINA
  • Opioids Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • Table 44: China Recent Past, Current & Future Analysis for Opioids by Segment - Extended-Release / Long-Acting and Immediate-Release / Short-Acting - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 45: China Historic Review for Opioids by Segment - Extended-Release / Long-Acting and Immediate-Release / Short-Acting Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 46: China 16-Year Perspective for Opioids by Segment - Percentage Breakdown of Value Sales for Extended-Release / Long-Acting and Immediate-Release / Short-Acting for the Years 2014, 2024 & 2030
  • Table 47: China Recent Past, Current & Future Analysis for Opioids by End-Use - Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 48: China Historic Review for Opioids by End-Use - Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 49: China 16-Year Perspective for Opioids by End-Use - Percentage Breakdown of Value Sales for Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction for the Years 2014, 2024 & 2030
EUROPE
  • Opioids Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • Table 50: Europe Recent Past, Current & Future Analysis for Opioids by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 51: Europe Historic Review for Opioids by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 52: Europe 16-Year Perspective for Opioids by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
  • Table 53: Europe Recent Past, Current & Future Analysis for Opioids by Segment - Extended-Release / Long-Acting and Immediate-Release / Short-Acting - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 54: Europe Historic Review for Opioids by Segment - Extended-Release / Long-Acting and Immediate-Release / Short-Acting Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 55: Europe 16-Year Perspective for Opioids by Segment - Percentage Breakdown of Value Sales for Extended-Release / Long-Acting and Immediate-Release / Short-Acting for the Years 2014, 2024 & 2030
  • Table 56: Europe Recent Past, Current & Future Analysis for Opioids by End-Use - Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 57: Europe Historic Review for Opioids by End-Use - Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 58: Europe 16-Year Perspective for Opioids by End-Use - Percentage Breakdown of Value Sales for Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction for the Years 2014, 2024 & 2030
FRANCE
  • Opioids Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • Table 59: France Recent Past, Current & Future Analysis for Opioids by Segment - Extended-Release / Long-Acting and Immediate-Release / Short-Acting - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 60: France Historic Review for Opioids by Segment - Extended-Release / Long-Acting and Immediate-Release / Short-Acting Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 61: France 16-Year Perspective for Opioids by Segment - Percentage Breakdown of Value Sales for Extended-Release / Long-Acting and Immediate-Release / Short-Acting for the Years 2014, 2024 & 2030
  • Table 62: France Recent Past, Current & Future Analysis for Opioids by End-Use - Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 63: France Historic Review for Opioids by End-Use - Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 64: France 16-Year Perspective for Opioids by End-Use - Percentage Breakdown of Value Sales for Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction for the Years 2014, 2024 & 2030
GERMANY
  • Opioids Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • Table 65: Germany Recent Past, Current & Future Analysis for Opioids by Segment - Extended-Release / Long-Acting and Immediate-Release / Short-Acting - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 66: Germany Historic Review for Opioids by Segment - Extended-Release / Long-Acting and Immediate-Release / Short-Acting Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 67: Germany 16-Year Perspective for Opioids by Segment - Percentage Breakdown of Value Sales for Extended-Release / Long-Acting and Immediate-Release / Short-Acting for the Years 2014, 2024 & 2030
  • Table 68: Germany Recent Past, Current & Future Analysis for Opioids by End-Use - Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 69: Germany Historic Review for Opioids by End-Use - Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 70: Germany 16-Year Perspective for Opioids by End-Use - Percentage Breakdown of Value Sales for Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction for the Years 2014, 2024 & 2030
ITALY
  • Table 71: Italy Recent Past, Current & Future Analysis for Opioids by Segment - Extended-Release / Long-Acting and Immediate-Release / Short-Acting - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 72: Italy Historic Review for Opioids by Segment - Extended-Release / Long-Acting and Immediate-Release / Short-Acting Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 73: Italy 16-Year Perspective for Opioids by Segment - Percentage Breakdown of Value Sales for Extended-Release / Long-Acting and Immediate-Release / Short-Acting for the Years 2014, 2024 & 2030
  • Table 74: Italy Recent Past, Current & Future Analysis for Opioids by End-Use - Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 75: Italy Historic Review for Opioids by End-Use - Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 76: Italy 16-Year Perspective for Opioids by End-Use - Percentage Breakdown of Value Sales for Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction for the Years 2014, 2024 & 2030
UNITED KINGDOM
  • Opioids Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • Table 77: UK Recent Past, Current & Future Analysis for Opioids by Segment - Extended-Release / Long-Acting and Immediate-Release / Short-Acting - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 78: UK Historic Review for Opioids by Segment - Extended-Release / Long-Acting and Immediate-Release / Short-Acting Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 79: UK 16-Year Perspective for Opioids by Segment - Percentage Breakdown of Value Sales for Extended-Release / Long-Acting and Immediate-Release / Short-Acting for the Years 2014, 2024 & 2030
  • Table 80: UK Recent Past, Current & Future Analysis for Opioids by End-Use - Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 81: UK Historic Review for Opioids by End-Use - Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 82: UK 16-Year Perspective for Opioids by End-Use - Percentage Breakdown of Value Sales for Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction for the Years 2014, 2024 & 2030
SPAIN
  • Table 83: Spain Recent Past, Current & Future Analysis for Opioids by Segment - Extended-Release / Long-Acting and Immediate-Release / Short-Acting - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 84: Spain Historic Review for Opioids by Segment - Extended-Release / Long-Acting and Immediate-Release / Short-Acting Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 85: Spain 16-Year Perspective for Opioids by Segment - Percentage Breakdown of Value Sales for Extended-Release / Long-Acting and Immediate-Release / Short-Acting for the Years 2014, 2024 & 2030
  • Table 86: Spain Recent Past, Current & Future Analysis for Opioids by End-Use - Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 87: Spain Historic Review for Opioids by End-Use - Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 88: Spain 16-Year Perspective for Opioids by End-Use - Percentage Breakdown of Value Sales for Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction for the Years 2014, 2024 & 2030
RUSSIA
  • Table 89: Russia Recent Past, Current & Future Analysis for Opioids by Segment - Extended-Release / Long-Acting and Immediate-Release / Short-Acting - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 90: Russia Historic Review for Opioids by Segment - Extended-Release / Long-Acting and Immediate-Release / Short-Acting Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 91: Russia 16-Year Perspective for Opioids by Segment - Percentage Breakdown of Value Sales for Extended-Release / Long-Acting and Immediate-Release / Short-Acting for the Years 2014, 2024 & 2030
  • Table 92: Russia Recent Past, Current & Future Analysis for Opioids by End-Use - Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 93: Russia Historic Review for Opioids by End-Use - Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 94: Russia 16-Year Perspective for Opioids by End-Use - Percentage Breakdown of Value Sales for Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction for the Years 2014, 2024 & 2030
REST OF EUROPE
  • Table 95: Rest of Europe Recent Past, Current & Future Analysis for Opioids by Segment - Extended-Release / Long-Acting and Immediate-Release / Short-Acting - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 96: Rest of Europe Historic Review for Opioids by Segment - Extended-Release / Long-Acting and Immediate-Release / Short-Acting Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 97: Rest of Europe 16-Year Perspective for Opioids by Segment - Percentage Breakdown of Value Sales for Extended-Release / Long-Acting and Immediate-Release / Short-Acting for the Years 2014, 2024 & 2030
  • Table 98: Rest of Europe Recent Past, Current & Future Analysis for Opioids by End-Use - Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 99: Rest of Europe Historic Review for Opioids by End-Use - Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 100: Rest of Europe 16-Year Perspective for Opioids by End-Use - Percentage Breakdown of Value Sales for Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction for the Years 2014, 2024 & 2030
ASIA-PACIFIC
  • Opioids Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • Table 101: Asia-Pacific Recent Past, Current & Future Analysis for Opioids by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 102: Asia-Pacific Historic Review for Opioids by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 103: Asia-Pacific 16-Year Perspective for Opioids by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
  • Table 104: Asia-Pacific Recent Past, Current & Future Analysis for Opioids by Segment - Extended-Release / Long-Acting and Immediate-Release / Short-Acting - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 105: Asia-Pacific Historic Review for Opioids by Segment - Extended-Release / Long-Acting and Immediate-Release / Short-Acting Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 106: Asia-Pacific 16-Year Perspective for Opioids by Segment - Percentage Breakdown of Value Sales for Extended-Release / Long-Acting and Immediate-Release / Short-Acting for the Years 2014, 2024 & 2030
  • Table 107: Asia-Pacific Recent Past, Current & Future Analysis for Opioids by End-Use - Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 108: Asia-Pacific Historic Review for Opioids by End-Use - Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 109: Asia-Pacific 16-Year Perspective for Opioids by End-Use - Percentage Breakdown of Value Sales for Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and Deaddiction for the Years 2014, 2024 & 2030
AUSTRALIA
  • Opioids Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
INDIA
  • Opioids Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
SOUTH KOREAREST OF ASIA-PACIFIC
LATIN AMERICA
  • Opioids Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
ARGENTINABRAZILMEXICOREST OF LATIN AMERICA
MIDDLE EAST
  • Opioids Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
IRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EAST
AFRICA
  • Opioids Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
IV. COMPETITION

Companies Mentioned

  • Egalet Corporation
  • Janssen Pharmaceuticals, Inc.
  • Pfizer, Inc.
  • Purdue Pharma LP
  • Sanofi
  • Sun Pharmaceutical Industries Ltd.
  • West-Ward Pharmaceuticals Corporation

Table Information